Scalper1 News
Big pharma Pfizer (PFE) was down 2.5% in morning trading on the stock market today after its breast-cancer drug palbociclib did well in trials but fell a bit short of sky-high expectations. At the American Association for Cancer Research meeting on Sunday, Pfizer presented final results from its phase-two trial of palbo in patients with metastatic breast cancer. As IBD reported last month, investors were greatly interested in the presentation Scalper1 News
Scalper1 News